Loading…
Collegium Pharmaceutical, Inc. is projected to rise to $40.07 by 2027, a +13% move from its current price of $35.39. COLL is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $34.82 | $35.41 | $36.01 | +0.06% |
| Aug 3 | $34.60 | $35.43 | $36.28 | +0.11% |
| Aug 4 | $34.44 | $35.45 | $36.49 | +0.17% |
| Aug 5 | $34.30 | $35.47 | $36.68 | +0.22% |
| Aug 6 | $34.19 | $35.49 | $36.84 | +0.28% |
| Aug 7 | $34.08 | $35.51 | $36.99 | +0.34% |
| Aug 8 | $33.99 | $35.53 | $37.14 | +0.39% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $33.99 | $35.53 | $37.14 | +0.39% |
| Week 2 | $33.51 | $35.67 | $37.97 | +0.79% |
| Week 3 | $33.17 | $35.81 | $38.66 | +1.18% |
| Week 4 | $32.91 | $35.95 | $39.27 | +1.58% |
| Week 5 | $32.69 | $36.09 | $39.84 | +1.98% |
| Week 6 | $32.51 | $36.23 | $40.38 | +2.38% |
| Week 7 | $32.36 | $36.37 | $40.89 | +2.78% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company that engages in the development and commercialization of medicines for pain management. Its portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
The stock is currently priced at $35.20 per share. It has a market capitalization of $1.14B and ranks 2321 by market cap. The forecast horizon shows upside potential, with the 2026 avg price at $35.20 and the 2030 avg price at $55.98, and the 2050 avg price at $268.56.
The forecast also shows rising max values and ROI: 2026 max $46.38 (ROI 0%), 2030 max $76.39 (ROI 59%), 2040 max $209.91 (ROI 290%), and 2050 max $440.53 (ROI 663%).
A major floor 13.9% below — a decisive break under it would weaken the trend.
The nearest floor, 5.5% below — buyers have tended to step in here.
The nearest ceiling, 5.9% above — a clean break opens room to run.
A major ceiling 11.5% above — clearing it would confirm fresh momentum.
Key COLL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of COLL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $35.82 | Sell | $35.72 | Sell |
| MA 10 | $35.60 | Sell | $35.71 | Sell |
| MA 20 | $35.78 | Sell | $35.62 | Sell |
| MA 50 | $34.80 | Buy | $35.36 | Buy |
| MA 100 | $34.59 | Buy | $36.01 | Sell |
| MA 200 | $39.33 | Sell | $36.73 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 49.14 | Neutral |
| Stoch RSI (14) | 25.63 | Neutral |
| CCI (20) | -52.24 | Neutral |
| Williams %R (14) | -66.50 | Info |
| MACD (12,26,9) | -0.06 | Sell |
| ROC (12) | -3.62 | Sell |
| Bollinger %B (20,2) | 0.35 | Neutral |
| Stochastic %K (14) | 33.50 | Neutral |
| TRIX (15) | 0.10 | Buy |
| Awesome (5,34) | 0.33 | Buy |
| Ultimate (7,14,28) | 57.72 | Neutral |
| Momentum (10) | -0.69 | Sell |
| Aroon Osc (25) | -48.00 | Sell |
| Hull MA (9) | 36.07 | Sell |
| ADX (14) | 7.95 | Neutral |
| ATR (14) | 0.56 | Info |
The 30-day sentiment is BULLISH. RSI(14) is 50, and the 50-day simple moving average is $34.64 while the 200-day simple moving average is $39.25. The stock trades within a 30-day range of $31.04 to $39.91, with a support at $33.45 and a resistance at $37.47. Annualized volatility is 40%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $30.48 | $35.39 | $46.38 | 0% | Neutral | |
| $32.86 | $40.07 | $51.07 | +13% | Neutral | |
| $33.32 | $41.41 | $54.23 | +17% | Neutral | |
| $38.98 | $49.20 | $65.81 | +39% | Bullish | |
| $43.08 | $55.11 | $75.06 | +56% | Bullish | |
| $48.91 | $63.34 | $87.64 | +79% | Bullish | |
| $56.05 | $73.41 | $103.02 | +107% | Bullish | |
| $57.19 | $75.69 | $107.60 | +114% | Bullish | |
| $59.78 | $79.91 | $114.96 | +126% | Bullish | |
| $62.47 | $84.29 | $122.62 | +138% | Bullish | |
| $93.48 | $131.57 | $200.60 | +272% | Bullish | |
| $169.55 | $255.96 | $418.38 | +623% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $30.48 | $35.39 | $43.42 | +0.00% |
| September 2026 | $32.01 | $37.53 | $45.01 | +6.05% |
| October 2026 | $31.62 | $37.24 | $44.99 | -0.77% |
| November 2026 | $31.49 | $37.24 | $45.26 | -0.01% |
| December 2026 | $31.99 | $37.95 | $46.38 | +1.92% |
Click any year to see its month-by-month COLL forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect COLL to range from $30.48 to $46.38 through 2026. The $35.39 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The COLL price prediction for 2027 points to an average of $40.07 (low $32.86, high $51.07) — a potential gain of +13% on today's $35.39. Price action looks broadly range-bound.
In 2028, COLL is projected to trade between $33.32 and $54.23, averaging $41.41 — a potential gain of +17% from today's $35.39. That is up +3% on the projected 2027 average. A consolidation phase looks the most probable path here.
Collegium Pharmaceutical, Inc.'s 2029 outlook centres on $49.20, within a $38.98 to $65.81 range. That is up +19% on the projected 2028 average. That marks a +39% change versus current levels. Momentum favours further upside here.
By 2030, COLL could reach as high as $75.06, with a base case around $55.11 and support toward $43.08 — roughly +56% from $35.39. Buyers look set to stay in control over this stretch.
Expect COLL to range from $48.91 to $87.64 through 2031. The $63.34 average target implies a +79% move from current prices. That is up +15% on the projected 2030 average. Momentum favours further upside here.
The COLL price prediction for 2032 points to an average of $73.41 (low $56.05, high $103.02) — a potential gain of +107% on today's $35.39. Buyers look set to stay in control over this stretch.
In 2033, COLL is projected to trade between $57.19 and $107.60, averaging $75.69 — a potential gain of +114% from today's $35.39. That is up +3% on the projected 2032 average. Momentum favours further upside here.
Collegium Pharmaceutical, Inc.'s 2034 outlook centres on $79.91, within a $59.78 to $114.96 range. That is up +6% on the projected 2033 average. That marks a +126% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, COLL could reach as high as $122.62, with a base case around $84.29 and support toward $62.47 — roughly +138% from $35.39. Momentum favours further upside here.
Expect COLL to range from $93.48 to $200.60 through 2040. The $131.57 average target implies a +272% move from current prices. That is up +56% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The COLL price prediction for 2050 points to an average of $255.96 (low $169.55, high $418.38) — a potential gain of +623% on today's $35.39. Momentum favours further upside here.
Investing $1,000 in COLL today (≈ 28.25657 COLL) could be worth
$7,232.58
+$6,232.58 (+623%) by 2050 · US Dollar
Based on the average projected COLL price of $255.96 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in COLLwould be worth at today's price.
$1,000 invested in COLL on Jul 31, 2025 (≈ 33.489618 COLL) would be worth
$1,185.2
+$185.2 (+18.5%) today · 1.19× · US Dollar
Based on a COLL entry price of $29.86 vs. today's $35.39.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $35.2 | $1,005.4 | +0.5% |
| 1 month ago | $35.87 | $986.62 | -1.3% |
| 3 months ago | $34.32 | $1,031.18 | +3.1% |
| 6 months ago | $47.11 | $751.22 | -24.9% |
| 1 year ago | $29.86 | $1,185.2 | +18.5% |
| All time (5.0y) ago | $24.96 | $1,417.87 | +41.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our COLL forecast.
Our base-case forecast reaches $71.00 around 2032.
Implied market cap at $71.00: $2.3B
The multi-year forecast points to a rising price trajectory, with the average price climbing from $35.20 in 2026 to $55.98 in 2030, $137.27 in 2040, and $268.56 in 2050. The 2030 avg of $55.98 carries a 59% ROI, while the 2040 avg of $137.27 carries a 290% ROI and the 2050 avg of $268.56 carries a 663% ROI. Sentiment shifts to BULLISH in several future years, and the upside includes a max of $76.39 in 2030, $209.91 in 2040, and $440.53 in 2050.
These figures are estimates and carry uncertainty.
Tap a question to reveal the answer.
Avg $55.98, min $43.69, max $76.39; ROI 59%; sentiment BULLISH.
Yes—the forecast max by 2032 is $106.02, which exceeds $100.
Forecasts show increasing averages over time: 2026 avg $35.20, 2035 avg $87.06, 2040 avg $137.27, 2050 avg $268.56; ROI reaches 663% by 2050; estimates.
Min $39.59, Avg $50.03, Max $67.05; ROI 42.1%; sentiment BULLISH.
Avg $137.27, min $97.25, max $209.91; ROI 290%; sentiment BULLISH.
Collegium Pharmaceutical, Inc. Community Discussion
0Share your Collegium Pharmaceutical, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.